Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2017年 / 59卷 / 1517期
关键词：
TRANSPLANTATION;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [1] Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
    Wilcox, M. H.
    Gerding, D. N.
    Poxton, I. R.
    Kelly, C.
    Nathan, R.
    Birch, T.
    Cornely, O. A.
    Rahav, G.
    Bouza, E.
    Lee, C.
    Jenkin, G.
    Jensen, W.
    Kim, Y. -S.
    Yoshida, J.
    Gabryelski, L.
    Pedley, A.
    Eves, K.
    Tipping, R.
    Guris, D.
    Kartsonis, N.
    Dorr, M. -B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04): : 305 - 317
  • [2] Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection
    Kufel, Wesley D.
    Devanathan, Aaron S.
    Marx, Ashley H.
    Weber, David J.
    Daniels, Lindsay M.
    PHARMACOTHERAPY, 2017, 37 (10): : 1298 - 1308
  • [3] Bezlotoxumab and Recurrent Clostridium difficile Infection Reply
    Wilcox, Mark
    Dorr, Mary-Beth
    Pedley, Alison
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1594 - 1596
  • [4] Recurrent Clostridium difficile infection treated with bezlotoxumab
    Palenzuela Afonso, Beatriz
    Caparros Nieto, Ana B.
    Gonzalez Cruz, Macarena
    Martinez Faci, Cristina
    ANALES DE PEDIATRIA, 2023, 98 (01): : 141 - 142
  • [5] Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
    Gerding, Dale N.
    Kelly, Ciaran P.
    Rahav, Galia
    Lee, Christine
    Dubberke, Erik R.
    Kumar, Princy N.
    Yacyshyn, Bruce
    Kao, Dina
    Eves, Karen
    Ellison, Misoo C.
    Hanson, Mary E.
    Guris, Dalya
    Dorr, Mary Beth
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (05) : 649 - 656
  • [6] Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium Difficile Infection (Reprinted from The Medical Letter on Drugs and Therapeutics, vol 59, pg 49, 2017)
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (07): : 659 - 660
  • [7] The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients
    Mikamo, Hiroshige
    Aoyama, Norihiro
    Sawata, Miyuki
    Fujimoto, Go
    Dorr, Mary Beth
    Yoshinari, Tomoko
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (02) : 123 - 129
  • [8] Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
    Navalkele, Bhagyashri D.
    Chopra, Teena
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 11 - 21
  • [9] The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review
    Thandavaram, Abhay
    Channar, Aneeta
    Purohit, Ansh
    Shrestha, Bijay
    Patel, Deepkumar
    Shah, Hriday
    Hanna, Kerollos
    Kaur, Harkirat
    Alazzeh, Mohammad S.
    Mohammed, Lubna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [10] Bezlotoxumab for the prevention of Clostridium difficile recurrence
    Couture-Cossette, Antoine
    Carignan, Alex
    Ilangumaran, Subburaj
    Valiquette, Louis
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (11) : 1439 - 1445
12345